Vault-13

SCILEX HOLDING CO SCLX

COM · Common Stock · CUSIP 80880W106

1 institutional holders -79 vs Q1 2025
3,0463.0k shares reported held*
$1.0kreported value*
0 new 0 added 0 reduced 78 sold out net sold ≈ $11.2m (-44.9m shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.33.

Trends to Q2 2025

Institutional holders

Managers reporting a position, each quarter

050100150Q4 22: 8Q1 23: 88Q2 23: 94Q3 23: 83Q4 23: 92Q1 24: 103Q2 24: 91Q3 24: 94Q4 24: 102Q1 25: 80Q2 25: 11Q4 22Q2 23Q4 23Q2 24Q4 24Q2 25
Numbers
QuarterHolders
Q4 20228
Q1 202388
Q2 202394
Q3 202383
Q4 202392
Q1 2024103
Q2 202491
Q3 202494
Q4 2024102
Q1 202580
Q2 20251

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
1000100Q3 23: 28 bought or addedQ3 23: 35 cut or sold outQ4 23: 33 bought or addedQ4 23: 17 cut or sold outQ4 23Q1 24: 46 bought or addedQ1 24: 21 cut or sold outQ2 24: 26 bought or addedQ2 24: 42 cut or sold outQ2 24Q3 24: 28 bought or addedQ3 24: 19 cut or sold outQ4 24: 35 bought or addedQ4 24: 22 cut or sold outQ4 24Q1 25: 24 bought or addedQ1 25: 40 cut or sold outQ2 25: 0 bought or addedQ2 25: 78 cut or sold outQ2 25
Numbers
QuarterBought or addedCut or sold out
Q3 20232835
Q4 20233317
Q1 20244621
Q2 20242642
Q3 20242819
Q4 20243522
Q1 20252440
Q2 2025078

Calls vs puts

Options held, notional value, last 4 quarters. P/C = puts ÷ calls

CallsPuts
$0$200k$400k$600kQ3 24 calls: $426.9kQ3 24 puts: $58.3kQ3 24P/C 0.14Q4 24 calls: $38.6kQ4 24 puts: $32.3kQ4 24P/C 0.84Q1 25 calls: $6.2kQ1 25 puts: $2.8kQ1 25P/C 0.45Q2 25 calls: $0Q2 25 puts: $0Q2 25P/C —
Numbers
QuarterCallsPutsP/C
Q3 2024$426.9k$58.3k0.14
Q4 2024$38.6k$32.3k0.84
Q1 2025$6.2k$2.8k0.45
Q2 2025$0$0—

Biggest buyers

None

Biggest sellers

ARMISTICE CAPITAL, LLC Sold out -13,792,000-13.8m
STATE STREET CORP Sold out -7,590,420-7.6m
BlackRock, Inc. Sold out -6,736,405-6.7m
VANGUARD GROUP INC Sold out -5,897,715-5.9m
GEODE CAPITAL MANAGEMENT, LLC Sold out -1,609,964-1.6m
NORTHERN TRUST CORP Sold out -1,345,024-1.3m
RA CAPITAL MANAGEMENT, L.P. Sold out -1,036,218-1.0m
UBS Group AG Sold out -731,541-731.5k
D. E. Shaw & Co., Inc. Sold out -627,038-627.0k
Rafferty Asset Management, LLC Sold out -620,131-620.1k

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
SCLX Stock Acquisition JV LLC 13D · may seek influence -1.7 pts · filed 2025-01-23
Stated purposeItem 4 of the Schedule 13D is hereby amended and supplemented as follows: Romeg License Amendment On January 16, 2025, the Issuer entered into a First Amendment to License and Commercialization Agreement (the "License Amendment") with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC ("Romeg") to amend a previously executed license agreement. In consideration of the execution of the License Amendment, and as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of Common Stock, held by the Reporting Person. Amendment to Senior Secured Promissory Note As previously disclosed by the Issuer, the Issuer issued a Senior Secured Promissory Note, dated as of September 21, 2023, t… Full filing
21.1% -1.7 pts 80.6m 2025-01-23
ORAMED PHARMACEUTICALS INC. 13G · passive investor +3.7 pts · filed 2025-05-08 9.9% +3.7 pts 732.7k 2025-05-08

Insider purchases and sales in Q2 2025

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

Officers and directors buying vs selling

Number of people, by quarter (10% owners not included)

BuyingSelling
10010Q3 23: 0 buyingQ3 23: 0 sellingQ4 23: 0 buyingQ4 23: 0 sellingQ4 23Q1 24: 0 buyingQ1 24: 0 sellingQ2 24: 4 buyingQ2 24: 0 sellingQ2 24Q3 24: 0 buyingQ3 24: 0 sellingQ4 24: 7 buyingQ4 24: 0 sellingQ4 24Q1 25: 0 buyingQ1 25: 0 sellingQ2 25: 0 buyingQ2 25: 0 sellingQ2 25
Numbers
QuarterBuyingBoughtSellingSoldSold under a plan
Q3 20230—0——
Q4 20230—0——
Q1 20240—0——
Q2 20244$230.3k0——
Q3 20240—0——
Q4 20247$126.3k0——
Q1 20250—0——
Q2 20250—0——

None reported in Q2 2025.

Holders, Q2 2025

#ManagerLocationShares Value% of their portfolioChangeShares change
1 AMALGAMATED BANK 0.00% of their portfolio NEW YORK, NY 3,0463.0k $1.0k $1.0k 0.00% Unchanged